Please assess the completion status of the following clinical trial:

Trial Title: Biological Therapy in Treating Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed advanced malignancy that expresses HER2/neu~  * Stage IIA breast cancer with more than 6 positive lymph nodes~ * Stage IIB, IIIA, or IIIB breast cancer~ * Stage III ovarian cancer~ * Lymph node positive gastric cancer~ * Metastatic tumor~* No measurable or evaluable disease after standard treatment~* No previously irradiated or newly diagnosed CNS metastases~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Menopausal status:~* Not specified~Performance status:~* Karnofsky 80-100%~Life expectancy:~* Greater than 6 months~Hematopoietic:~* WBC at least 3,000/mm\^3~* Hemoglobin at least 9 mg/dL~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin less than 2.0 mg/dL~* No hepatic disease, including viral hepatitis~Renal:~* Creatinine less than 2.5 mg/dL~Cardiovascular:~* No New York Heart Association class III or IV heart disease~Pulmonary:~* No asthma or chronic obstructive pulmonary disease~Immunologic:~* Must have positive intradermal delayed hypersensitivity test for at least 1 of the following:~  * Candida~ * Mumps~ * Tetanus~ * Trichophyton~ * Histoplasmin~* No prior autoimmune disease including, but not limited to, the following:~  * Inflammatory bowel disease~ * Systemic lupus erythematosus~ * Ankylosing spondylitis~ * Scleroderma~ * Multiple sclerosis~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* Hepatitis B surface antigen and hepatitis C antibody negative~* No other concurrent serious chronic or acute illness or infection (including urinary tract infection)~* No known shellfish or iodine allergy~* No other prior or concurrent malignancy except for nonmelanoma skin cancer, cervical cancer, or controlled superficial bladder cancer~* No medical or psychological condition that may preclude study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No other concurrent immunotherapy~Chemotherapy:~* At least 4 weeks since prior chemotherapy and recovered~* No concurrent chemotherapy~Endocrine therapy:~* Concurrent hormonal therapy allowed (tamoxifen, raloxifene, toremifene, and all aromatase inhibitors)~* At least 4 weeks since prior steroid or immunosuppressive therapy (e.g, azathioprine or cyclosporine)~Radiotherapy:~* Prior radiotherapy allowed except to cranium~* At least 4 weeks since prior radiotherapy and recovered~* At least 12 weeks since prior strontium chloride Sr 89~* No concurrent radiotherapy~Surgery:~* At least 4 weeks since prior surgery and recovered~Other:~* Concurrent bisphosphonates allowed~* No prior hepatitis B immunization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete